Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'.

Dankner, Matthew

Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'. [electronic resource] - British journal of cancer 05 2018 - 1276-1277 p. digital

Publication Type: Letter; Comment

1532-1827

10.1038/s41416-018-0012-2 doi


Antibodies, Monoclonal
Biomarkers
Cetuximab
Colorectal Neoplasms
ErbB Receptors--genetics
Genomics
Humans
Mutation
Proto-Oncogene Proteins B-raf--genetics